ARTICLE | Company News
CHMP backs Takeda's vedolizumab
March 22, 2014 12:54 AM UTC
EMA's CHMP recommended approval of Entyvio vedolizumab from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in patie...